Donanemab showed benefits in a Phase 3 trial involving early AD subjects [5], and ALZ-801/valiltramiprosate showed significant biomarker effects and promising clinical effects in a Phase 2 trial involving early AD subjects who were APOE4 carriers [26,58]. The gene discussed is APOE; the disease is Alzheimer disease.